nist micronutrients measurement quality assurance program ... · • a cover letter for the current...
TRANSCRIPT
-
[Tot
al R
etin
ol],
µg/m
L
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b
[Ana
lyte
], µg
/mL
340
350
437
428
433
438
430
434
439
358
364
374
386
399
408
416
426
440
382
395
421
441
NISTIR 7880-48
NIST Micronutrients Measurement Quality Assurance Program Winter and Summer 2017 Comparability Studies
Results for Round Robins LXXXI and LXXXII Fat-Soluble Vitamins and Carotenoids in Human Serum
FSV RR LXXXI
David L. Duewer Jeanice B. Thomas
This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.7880-48
FSV RR LXXXII
https://doi.org/10.6028/NIST.IR.7880-48
-
NISTIR 7880-48
NIST Micronutrients Measurement Quality Assurance Program Winter and Summer 2017 Comparability Studies
Results for Round Robins LXXXI and LXXXII Fat-Soluble Vitamins and Carotenoids in Human Serum
David L. Duewer Jeanice B. Thomas
Chemical Sciences Division Material Measurement Laboratory
This publication is available free of charge from: https://doi.org/10.6028/NIST.IR.7880-48
January 2018
U.S. Department of Commerce Wilbur L. Ross, Jr., Secretary
National Institute of Standards and Technology Walter Copan, NIST Director and Undersecretary of Commerce for Standards and Technology
https://doi.org/10.6028/NIST.IR.7880-48
-
(This page intentionally blank)
ii
-
Abstract _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The National Institute of Standards and Technology coordinates the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat-soluble vitamins and carotenoids in human serum and plasma. This report describes the design of and results for the Winter and Summer 2017 MMQAP measurement comparability improvement studies: 1) Round Robin LXXXI Fat-Soluble Vitamins and Carotenoids in Human Serum (RR81) and 2) Round Robin LXXXII Fat-Soluble Vitamins and Carotenoids in Human Serum (RR82). To avoid increasing participation fees, the overhead costs for these programs were minimized by shipping the materials for both studies in the same package in February 2017. Participants were requested not to analyze the Summer samples before June 5, 2017 but to provide their measurement results by September 4, 2017. Participants were reminded of the due-date by e-mail in early August 2017.
Keywords
Human Serum Retinol, α-Tocopherol, γ-Tocopherol, Total and Trans-β-Carotene
iii
-
Table of Contents _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Abstract............................................................................................................................................... iii Keywords ............................................................................................................................................ iii Table of Contents ............................................................................................................................... iv Introduction......................................................................................................................................... 1 Round Robin LXXXI: Fat-Soluble Vitamins and Carotenoids in Human Serum...................... 1 Round Robin LXXXII: Fat-Soluble Vitamins and Carotenoids in Human Serum .................... 2 References ............................................................................................................................................ 3
Appendix A. Shipping Package Inserts for RR81 and RR82 ..................................................... A1 Appendix B. Final Report for RR81 .............................................................................................. B1 Appendix C. “All-Lab Report” for RR81...................................................................................... C1 Appendix D. Representative “Individualized Report” for RR81 ............................................... D1 Appendix E. Final Report for RR82 .............................................................................................. E1 Appendix F. “All-Lab Report” for RR82 ...................................................................................... F1 Appendix G. Representative “Individualized Report” for RR82............................................... G1
iv
-
Introduction _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Beginning in 1984, the National Institute of Standards and Technology (NIST) coordinated the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. The MMQAP provided participants with measurement comparability assessment through use of interlaboratory studies, Standard Reference Materials (SRMs) and control materials, and methods development and validation. Serum-based samples with assigned values for the target analytes (retinol, alpha-tocopherol, gamma/beta-tocopherol, trans- and total beta-carotene, and total ascorbic acid) and performance-evaluation standards were distributed by NIST to laboratories for analysis.
Participants used the methodology of their choice to determine analyte content in the control and study materials. Participants provided their data to NIST, where it was compiled and evaluated for trueness relative to the NIST value, within-laboratory precision, and concordance within the participant community. NIST provided the participants with a technical summary report concerning their performance for each exercise and suggestions for methods development and refinement. Participants who had concerns regarding their laboratory’s performance were encouraged to consult with the MMQAP coordinators.
All MMQAP interlaboratory studies consisted of individual units of batch-prepared samples that were distributed to each participant. For historical reasons these studies are referred to as “Round Robins”. The MMQAP program and the nature of its studies are described elsewhere. [1,2]
Note: MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXXXII (hereafter referred to as RR82) was the final MMQAP-coordinated study. Future studies of considerably different focus and design will be coordinated through the Health Assessment Measurements Quality Assurance Program (HAMQAP). Information about HAMQAP and other NIST Quality Assurance Programs is available at https://qa.nist.gov.
Round Robin LXXXI: Fat-Soluble Vitamins and Carotenoids in Human Serum
Participants in the MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXXXI comparability study (hereafter referred to as RR81) received five liquid-frozen human serum test samples for analysis plus two liquid-frozen bovine serum optional samples. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in February 2017 in the same shipping package as the RR82 materials but in separate clearly labeled plastic bags. Participants were requested to provide their measurement results by May 15, 2017. The communication materials included in the sample shipment are provided in Appendix A.
Participants were requested to report values for all fat-soluble vitamin-related analytes of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.
The final report delivered to every participant in RR81 consists of three documents:
1
https://qa.nist.gov/
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
• A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of the overall results that may be of broad interest. This cover letter is reproduced as Appendix B.
• The “All-Lab Report” that lists all of the reported measurement results, a number of consensus statistics for analytes reported by more than one participant, and the mean median and pooled SD from any prior distributions of the serum. This report also provides a numerical “score card” for each participant’s measurement comparability for the more commonly reported analytes. This All-Lab Report is reproduced as Appendix C.
• An “Individualized Report” that graphically analyzes each participant’s results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [2]. An example Individualized Report is reproduced as Appendix D.
Round Robin LXXXII: Fat-Soluble Vitamins and Carotenoids in Human Serum
Participants in RR82 received five liquid-frozen human serum test samples for analysis. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in February 2017 in the same shipping package as the RR81 materials but in separate clearly labeled plastic bags. Participants were requested not to analyze any of the RR82 samples before June 5, 2017 but to provide their measurement results by September 4, 2017. The communication materials included in the sample shipment are provided in Appendix A.
Participants were requested to report values for all fat-soluble vitamin-related analytes of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.
The final report delivered to every participant in RR82 consists of three documents:
• A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of overall results that may be of broad interest. This cover letter is reproduced as Appendix E.
• The “All-Lab Report” that summarizes all of the reported measurement results and provides several consensus statistics. This All-Lab Report is reproduced as Appendix F.
• An “Individualized Report” that graphically analyzes each participant’s results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [2]. An example Individualized Report is reproduced as Appendix G.
2
-
References _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
1 Duewer DL, Brown Thomas J, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat-Soluble Vitamin-Related Compounds in Human Sera. Anal Chem 1997;69(7):1406-1413.
2 Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT, Sowell AL. Micronutrients Measurement Quality Assurance Program: Helping Participants Use Interlaboratory Comparison Exercise Results to Improve Their Long-Term Measurement Performance. Anal Chem 1999;71(9):1870-1878.
3
-
Appendix A. Shipping Package Inserts for RR81 and RR82 _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The following items were included in each package shipped to the Round Robin LXXXI (RR81) and LXXXII (RR82) participants:
• Combined cover letter for RRR81 and RR82. • Datasheets for
o five human serum test samples for RR81, o two bovine serum optional samples for RR81, and o five human serum test samples for RR82.
• Packing List and Shipment Receipt Confirmation form for RR81 and RR82 samples.
This RR81 samples were enclosed in a bubble-wrapped sealed plastic bag that was labeled:
NIST MMQAP-FSV: RR LXXXI Micronutrients Measurement Fat-Soluble Vitamins
Quality Assurance Program
Winter 2017 Samples Results due on or before:
May 15, 2017
The RR82 samples were enclosed in a bubble-wrapped sealed plastic bag that was labeled:
NIST MMQAP-FSV: RR LXXXII Micronutrients Measurement Fat-Soluble Vitamins
Quality Assurance Program
Summer 2017 Samples Analyze after: June 5, 2017
Results due on or before: September 4, 2017
The Packing List and Shipment Receipt Confirmation form was placed at the top of the shipping box, between the cardboard covering and the foam insulation.
A1
-
FebruarY 27, 2017\ UNITED STATES DEPARTMENT OF COMMERCENational Institute of Standards and echflOt0gV8jhersbUrg. Marafld 20899
Dear ColleagUe
Enclosed are samples for the fatsolUble vitaminS and carotenoids in serum studies for the 2017 NISTMicronutrients Measurement Quali Assurance Program. Sample details are provided below.
RR8IRR81 ExploratorY (Bovine Serum)RR82
RR8 1 and RR82 consist of one vial each of five liquidfr0zen serum samples for analysis. As an exploratorYstudy for the development of a candidate reference mateflal for carotenoids, we also enclose two vials of abovine serum to be analyzed along with the RR8I human samples. All samples should be stored in the darkat or below —20 °C upon receipt. A form for each study is included for reporting your results. Please reportone value for each analyte for each serum sample on the appropriate data sheet If a value obtained is belowyour limit of quantiflCati0n please indicate this result on the form as “nq” (Not Quanted) or “
-
Participant #: ________ Date: _____________
Round Robin LXXXI: Human Sera NIST Micronutrients Measurement Quality Assurance Program
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Analyte 432 433 434 435 436 Units* total retinol
trans-retinol retinyl palmitate
α-tocopherol γ/β-tocopherol δ-tocopherol
total β-carotene trans-β-carotene
total cis-β-carotene total α-carotene
total lycopene trans-lycopene
total β-cryptoxanthin total α-cryptoxanthin
total lutein total zeaxanthin
total lutein&zeaxanthin astaxanthin
total coenzyme Q10 phylloquinone (K1)
25-hydroxyvitamin D phytoene
phytofluene
* We prefer µg/mL Were the samples frozen when received? Yes | No
Comments:
Mail: M2QAP Please return results by NIST, Stop 8392 15-May-2017 Fax: 301-977-0685 Gaithersburg, MD 20899-8392 A3 Email: [email protected]
-
Participant #: ________ Date: _____________
Round Robin LXXXI Exploratory: Bovine Serum NIST Micronutrients Measurement Quality Assurance Program
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Analyte BS-1a BS-1b Units* total retinol
trans-retinol retinyl palmitate
α-tocopherol γ/β-tocopherol δ-tocopherol
total β-carotene trans-β-carotene
total cis-β-carotene total α-carotene
total lycopene trans-lycopene
total β-cryptoxanthin total α-cryptoxanthin
total lutein total zeaxanthin
total lutein&zeaxanthin astaxanthin
total coenzyme Q10 phylloquinone (K1)
25-hydroxyvitamin D phytoene
phytofluene
Were the samples frozen when received? Yes | No We prefer µg/mL
Comments:
Mail: M2QAP NIST, Stop 8392 Gaithersburg, MD 20899-8392
Please return results by 15-May-2017
A4 Fax: 301-977-0685
Email: [email protected]
-
Participant #: ________ Date: _____________
Round Robin LXXXII: Human Sera NIST Micronutrients Measurement Quality Assurance Program
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Analyte 437 438 439 440 441 Units* total retinol
trans-retinol retinyl palmitate
α-tocopherol γ/β-tocopherol δ-tocopherol
total β-carotene trans-β-carotene
total cis-β-carotene total α-carotene
total lycopene trans-lycopene
total β-cryptoxanthin total α-cryptoxanthin
total lutein total zeaxanthin
total lutein&zeaxanthin astaxanthin
total coenzyme Q10 phylloquinone (K1)
25-hydroxyvitamin D phytoene
phytofluene
* We prefer µg/mL Were the samples frozen when received? Yes | No
Comments:
Mail: M2QAP Please return results by NIST, Stop 8392 4-September-2017 Fax: 301-977-0685 Gaithersburg, MD 20899-8392 A5 Email: [email protected]
-
Participant #: ________ Date: _____________
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Round Robins LXXXI and LXXXII: Human Sera NIST Micronutrients Measurement Quality Assurance Program
Packing List and Shipment Receipt Confirmation Form This box contains one (or more) sets of samples for both RR81 and RR82
There are five RR81 samples per (blue-labeled) set. They are: Serum Form Reconstitute? Vial/Cap #432 Liquid frozen No 2 mL amber / red #433 Liquid frozen No 3 mL amber / black #434 Liquid frozen No 3 mL amber / gold #435 Liquid frozen No 2 mL amber / metallic green #436 Liquid frozen No 2 mL amber / green
There are two RR81 Exploratory samples per (blue-labeled) set. They are: Serum Form Reconstitute? Vial/Cap BS-1a Liquid frozen No plastic / purple BS-1b Liquid frozen No plastic / purple
There are five RR82 samples per (orange-labeled) set. They are: Serum Form Reconstitute? Vial/Cap #437 Liquid frozen No 2 mL amber / silver #438 Liquid frozen No 3 mL amber / black #439 Liquid frozen No 3 mL amber / gold #440 Liquid frozen No 3 mL amber / blue #441 Liquid frozen No 2 mL clear / forest green
Please 1) Open the sample sets immediately 2) Check that each sets contains the appropriate samples 3) Store the sera at -20 ˚C or below until analysis 4) Email ([email protected]) or fax (301-977-0685) us the following info:
1) Date this shipment arrived: ___________________________ 2) Are all ten sera vials intact? Yes | No If "No", which one(s) were damaged?
3) Did the samples arrive frozen? Yes | No 4) At what temperature are you storing the serum samples? _______ ˚C
Your prompt return of this information is appreciated.
Mail: M2QAP Please return this sheet as soon as possible after checking the samples NIST, Stop 8392 Fax: 301-977-0685
Gaithersburg, MD 20899-8392 A6 Email: [email protected]
-
Appendix B. Final Report for RR81 _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The following three pages are the final report for RR81 as provided to all participants: • Cover letter. • An information sheet that:
o describes the contents of the “All-Lab” report, o describes the content of the “Individualized” report, o describes the nature of the test samples and details their previous distributions,
if any, and o summarizes aspects of the study that we believe may be of interest to the
participants.
B1
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-8390
June 20, 2017
Dear Colleague:
Enclosed is the summary report of the results for “Round Robin” LXXXI (RR81) of the 2017 NIST Micronutrients Measurement Quality Assurance Program (MMQAP) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability. RR81 (Sera 432 to 436) consisted of one vial each of five liquid-frozen serum samples. Also, included in this report are the results for the RR81 Exploratory study (BS-1a and BS-1b) which consisted of two vials of bovine serum. Details regarding the samples can be found in the enclosed report.
Your overall measurement comparability is summarized in the “Score Card” summary, page 7 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are >3 standard deviations from the assigned value. Similar information is presented graphically in the “target plots” that are the last page of your Individualized Report. If you have concerns regarding your laboratory’s performance, please contact us for consultation.
If you have questions or concerns regarding this report, please contact David Duewer at 301-975-3935; e-mail: [email protected] or me at 301-975-3120; e-mail: [email protected]; or fax: 301-978-0685.
Sincerely,
Jeanice Brown Thomas, MBA David L. Duewer, Ph.D. Research Chemist Research Chemometrician Chemical Sciences Division Chemical Sciences Division Material Measurement Laboratory Material Measurement Laboratory
Enclosures
B2
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The NIST MMQAP Round Robin LXXXI (RR81) report consists of: Page
1-5 A listing of all results and statistics for analytes reported by more than one participant.
6 The legend for the list of results and statistics.
7 The text Comparability Summary (Score Card) of measurement performance.
Page Individualized Report
1 Your values, the number of labs reporting values, and our assigned values.
2 to “Four Plot” summaries of your current and past measurement performance, one page for n each analyte you report that is also reported by at least eight other participants.
n+1 The graphical Comparability Summary (Target Plot) of measurement performance.
Samples. Five different liquid-frozen human serum samples were distributed to each participant in RR81. Two tubes of the same bovine serum were distributed as optional samples.
All-Lab Report
Serum
432
Description
Fresh-frozen, native, multi-donor, prepared in 2009.
Prior Distributions
#357:RR66-9/09, #365:RR67-3/10, This is Level 1 of SRM 968e. #375 RR69-3/11, #389:RR72-9/12,
#398:RR74-9/13, #403:RR75-3/14, #427:RR80-9/16
433 Fresh-frozen, native, multi-donor, prepared in 2015 #428:RR80-9/16 This is the candidate SRM 968f-Level 1.
434 Fresh-frozen, native, multi-donor, prepared in 2015 #430:RR80-9/16 This is the candidate SRM 968f-Level 2.
435 Liquid-frozen, native, multi-donor, prepared in 2008 #356:RR65-3/09, #360:RR66-9/09, #376:RR69-3/11, #391:RR72-9/12
436 Fresh-frozen, native, multi-donor, prepared in 2009. #359:RR66-9/09, #363:RR67-3/10, This is Level 3 of SRM 968e. #373:RR69-3/11, #379:RR70-9/11,
#400:RR74-9/13, #405:RR75-3/14, #429:RR80-9/16
BS-1a BS-1b
Fresh-frozen, native, single-donor bovine serum, purchased in 2016. These were optional samples.
First distribution
Results 1) Stability: There has been no significant change in the concentration nor variability of any analyte in
any of the human sera.
2) Bovine Serum BS-1, samples “a” and “b”: This material was distributed to evaluate the suitability of bovine sera as high β-carotene reference materials. We thank all who evaluated these samples.
Summary Report B3
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
No one reported analytical difficulties. The results for the duplicate samples were very similar for all analytes for all participants. For Total Retinol (Figure 1A) and α-Tocopherol (Figure 1B) the analytical variability as a function of analyte level is consistent with what we expect for human sera. However, the observed variability for β-Carotene is much greater than expected (Figure 1C). Further studies would be required to evaluate whether this variability results from matrix differences that impact chromatography/integration or from our limited experience with very high β-Carotene levels in sera.
0
0.02
0.04
0.06
0 0.2 0.4 0.6 0.8 1
RR81
eSD
, μg /
mL
Total Retinol
Human Bovine Expected
A
0.0
0.5
1.0
1.5
0 5 10 15 20
RR81
eSD
, μg /
mL
α-Tocopherol
Human Bovine Expected
B
RR81 Median, μg/mL RR81 Median, μg/mL
Total β-Carotene C 0.25
0.20
0.15
0.00
0.05
0.10
RR81
eSD
, μg /
mL
Human Bovine Expected
0 0.2 0.4 0.6 0.8
RR81 Median, μg/mL
Figure 1: Robust Standard Deviation (eSD) as Functions of Robust Location (Median). The lines denote the empirical relationships observed in the MMQAP studies from 1985 through 1995 as documented in Duewer et al, NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat Soluble Vitamin Related Compounds in Human Sera, Anal Chem 1997; 69:1406-1413.
Summary Report B4
-
Appendix C. “All-Lab Report” for RR81 _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The following seven pages are the “All-Lab Report” for RR81 as provided to all participants, with two exceptions:
• the participant identifiers (Lab) have been altered and • the order in which the participant results are listed has been altered.
The data summary in the “All-Lab Report” has been altered to ensure confidentiality of identification codes assigned to laboratories.
C1
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Rou
nd R
obin
LX
XX
I Lab
orat
ory
Res
ults
Tota
l Ret
inol
, μg/
mL
Ret
inyl
Pal
mita
te, μ
g/m
L α-
Toco
pher
ol, μ
g/m
L γ/
β-To
coph
erol
, μg/
mL
Lab
432
433
434
435
436
BS-1
a BS
-1b
C2
FSV-
BA
0.35
0 0.
330
0.66
0 0.
720
0.65
0 0.
280
0.28
0 FS
V-BD
0.
358
0.29
8 0.
672
0.81
4 0.
660
0.27
7 0.
262
FSV-
BE
0.35
0 0.
330
0.67
0 0.
760
0.66
0 FS
V-BH
0.
299
0.26
5 0.
586
0.61
3 0.
541
0.25
0 0.
246
FSV-
BJ
0.34
2 0.
309
0.65
7 0.
730
0.64
1 0.
267
0.26
4 FS
V-BL
0.
370
0.34
0 0.
690
0.80
0 0.
690
0.32
0 0.
290
FSV-
BM
0.29
0 0.
270
0.56
0 0.
620
0.69
0 0.
240
0.24
0 FS
V-BN
0.
395
0.36
4 0.
736
0.81
1 0.
708
0.30
4 0.
305
FSV-
BR
0.34
5 0.
331
0.66
0 0.
708
0.67
4 0.
239
0.23
5 FS
V-BS
FS
V-BT
0.
353
0.29
2 0.
687
0.72
6 0.
637
0.25
9 0.
252
FSV-
BU
0.32
6 0.
293
0.62
2 0.
567
0.61
7 0.
228
0.23
3 FS
V-BW
0.
346
0.33
6 0.
674
0.75
3 0.
647
0.26
0 0.
262
FSV-
CD
0.
330
0.38
0 0.
570
0.66
0 0.
530
0.21
0 0.
170
FSV-
CE
0.37
1 0.
337
0.66
7 0.
729
0.65
5 0.
276
0.27
9 FS
V-C
F 0.
393
0.33
9 0.
701
0.78
1 0.
711
0.27
5 0.
281
FSV-
CG
0.
317
0.29
7 0.
553
0.60
6 0.
561
2.43
0 0.
234
FSV-
CI
0.35
2 0.
312
0.67
3 0.
711
0.65
9 0.
229
0.22
8 FS
V-C
Z 0.
406
0.35
5 0.
722
0.84
6 0.
633
FSV-
DV
0.35
0 0.
322
0.59
4 0.
758
0.78
5 FS
V-EE
FSV-
FZ
0.33
0 0.
290
0.65
0 0.
720
0.64
0 0.
260
0.26
0 FS
V-G
D
0.35
9 0.
330
0.68
2 0.
743
0.66
8 0.
276
0.27
4 FS
V-G
E 0.
358
0.35
2 0.
779
0.79
6 0.
750
0.30
1 0.
278
FSV-
GF
FSV-
GG
FSV-
GJ
0.37
6 0.
326
0.64
9 0.
727
0.67
2 0.
275
0.29
9 FS
V-G
K 1.
657
1.58
9 3.
656
3.79
4 3.
153
1.29
1 1.
249
FSV-
GL
0.38
1 0.
341
0.68
6 0.
770
0.65
7 0.
268
0.26
9
432
433
434
435
436
BS-1
a BS
-1b
nd
nd
nd
0.02
1 0.
166
nd
nd
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Rou
nd R
obin
LX
XX
I Lab
orat
ory
Res
ults
δ-To
coph
erol
, μg/
mL
Tota
l β-C
arot
ene,
μg/
mL
trans
-β-C
arot
ene,
μg/
mL
Tota
l cis
-β-C
arot
ene,
μg/
mL
Lab
432
433
434
435
436
BS-1
a BS
-1b
C3
FSV-
BAFS
V-BD
FSV-
BEFS
V-BH
FSV-
BJFS
V-BL
FSV-
BMFS
V-BN
FSV-
BRFS
V-BS
FSV-
BTFS
V-BU
FSV-
BWFS
V-C
DFS
V-C
EFS
V-C
FFS
V-C
G0.
093
0.07
1 0.
075
0.09
0 0.
068
0.08
5 0.
086
FSV-
CI
FSV-
CZ
FSV-
DV
FSV-
EEFS
V-FZ
FSV-
GD
FSV-
GE
FSV-
GF
FSV-
GG
FSV-
GJ
FSV-
GK
nd
nd
nd
0.96
2 0.
535
nd
nd
FSV-
GL
432
433
434
435
436
BS-1
a BS
-1b
0.14
0 0.
160
0.28
0 0.
430
0.63
0 1.
220
1.16
0 0.
072
0.08
8 0.
166
0.23
4 0.
373
0.62
4 0.
605
0.07
5 0.
097
0.24
5 0.
317
0.56
1 0.
800
0.72
0
0.12
6 0.
144
0.23
6 0.
338
0.53
2 1.
007
1.00
7
≥0.0
89
≥0.1
16
≥0.1
64
≥0.2
27
≥0.3
31
≥0.4
36
≥0.4
56
0.10
6 0.
126
0.20
8 0.
287
0.42
4 0.
772
0.79
0 0.
102
na
0.19
4 0.
297
0.46
7 0.
844
0.85
8 0.
066
0.10
3 0.
178
0.28
7 0.
495
1.11
5 1.
063
0.10
0 0.
130
0.19
0 0.
310
0.39
0 0.
780
0.64
0 0.
089
0.10
0 0.
166
0.22
6 0.
399
0.55
7 0.
530
0.08
6 0.
101
0.20
5 0.
299
0.56
1 1.
220
1.22
3
0.14
4 0.
126
0.13
4 0.
170
0.34
5
0.09
1 0.
111
0.18
9 0.
275
0.42
6 0.
814
0.07
5 0.
070
0.08
6 0.
140
0.20
9 0.
440
≥0.0
62
≥0.1
39
≥0.3
37
≥0.6
55
≥0.9
72
≥1.6
96
≥1.7
99
0.11
4 0.
141
0.20
5 0.
316
0.47
4 0.
807
0.79
7 0.
494
0.79
4
432
433
434
435
436
BS-1
a BS
-1b
0.07
5 0.
093
0.17
6 0.
247
0.39
3 0.
705
0.68
7
0.08
9 0.
116
0.16
4 0.
227
0.33
1 0.
436
0.45
6 0.
097
0.10
8 0.
189
0.26
6 0.
392
0.67
0 0.
693
0.08
1 0.
094
0.19
2 0.
280
0.53
3 1.
068
1.07
4
0.07
9 0.
097
0.16
6 0.
242
0.37
5 0.
716
0.70
2
0.06
2 0.
139
0.33
7 0.
655
0.97
2 1.
696
1.79
9
432
433
434
435
436
BS-1
a BS
-1b
0.00
3 0.
005
0.01
0 0.
013
0.02
0 0.
081
0.08
2
0.01
0 0.
018
0.01
9 0.
022
0.03
2 0.
102
0.09
7
0.00
5 0.
005
0.01
3 0.
018
0.02
8 0.
152
0.14
9
0.012
0.014
0.023
0.033
0.051
0.098
0.095
n1
11
22
1 1
1413
1414
1413
13
66
66
6 6
6 4
4 4
4 4
4 4
Min
0.09
0 0.
068
0.06
6 0.
070
0.08
6 0.
140
0.20
9 0.
440
0.49
4 0.
062
0.09
3 0.
164
0.22
7 0.
331
0.43
6 0.
456
0.00
3 0.
005
0.01
0 0.
013
0.02
0 0.
081
0.08
2 M
edia
n0.
093
0.07
1 0.
075
0.52
6 0.
301
0.08
5 0.
086
0.09
6 0.
111
0.19
2 0.
292
0.44
7 0.
807
0.79
4 0.
080
0.10
3 0.
182
0.25
7 0.
392
0.71
0 0.
698
0.00
8 0.
010
0.01
6 0.
020
0.03
0 0.
100
0.09
6 M
ax0.
962
0.53
5 0.
144
0.16
0 0.
280
0.43
0 0.
630
1.22
0 1.
223
0.09
7 0.
139
0.33
7 0.
655
0.97
2 1.
696
1.79
9 0.
012
0.01
8 0.
023
0.03
3 0.
051
0.15
2 0.
149
eSD
0.02
9 0.
022
0.03
1 0.
036
0.09
6 0.
271
0.28
0 0.
010
0.01
3 0.
019
0.02
8 0.
058
0.23
3 0.
187
0.00
5 0.
007
0.00
7 0.
006
0.00
9 0.
016
0.01
1 eC
V30
20
16
12
22
34
35
13
1311
1115
33
27
65
71
43
32
31
16
12
Npa
st
9 5
8 20
1515
2021
6
66
77
7 6
7 M
edia
npas
t 0.
110
0.26
6 0.
210
0.09
1 0.
111
0.17
7 0.
275
0.40
2 0.
084
0.10
0 0.
179
0.24
9 0.
360
0.00
6 0.
014
0.02
0 SD
past
0.02
5 0.
023
0.03
0 0.
013
0.01
4 0.
024
0.03
1 0.
060
0.00
8 0.
022
0.01
9 0.
017
0.05
0 0.
003
0.00
4 0.
004
NAV
NAU
0.09
6 0.
111
0.19
2 0.
292
0.44
7 0.
080
0.10
3 0.
182
0.25
7 0.
392
0.00
8 0.
010
0.01
6 0.
020
0.03
0 0.
029
0.02
2 0.
031
0.04
3 0.
096
0.01
1 0.
013
0.02
1 0.
028
0.05
8 0.
801
0.70
4 0.
098
0.27
6 0.
211
All L
ab R
epor
t Pa
ge 2
/ 7
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Rou
nd R
obin
LX
XX
I Lab
orat
ory
Res
ults
Tota
l α-C
arot
ene,
μg/
mL
Tota
l Lyc
open
e, μ
g/m
L tra
ns-L
ycop
ene,
μg/
mL
Tota
l β-C
rypt
oxan
thin
, μg/
mL
Lab
432
433
434
435
436
BS-1
a BS
-1b
C4
FSV-
BAFS
V-BD
FSV-
BEFS
V-BH
0.00
5 0.
019
0.00
8 0.
041
0.01
1 0.
013
0.01
4 FS
V-BJ
0.01
4 0.
027
0.00
7 0.
050
0.00
5 0.
006
0.00
4 FS
V-BL
FSV-
BMFS
V-BN
0.03
3 0.
052
0.04
4 0.
097
0.05
7 0.
140
0.13
8 FS
V-BR
FSV-
BS0.
038
0.05
2 0.
056
0.07
3 0.
064
0.03
8 0.
038
FSV-
BT0.
010
0.02
4 0.
012
0.04
6 0.
014
0.01
6 0.
013
FSV-
BU0.
018
na
nd
0.05
0 0.
019
nd
0.01
5 FS
V-BW
nd
0.02
0 nd
ndnd
nd
nd
FSV-
CD
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Rou
nd R
obin
LX
XX
I Lab
orat
ory
Res
ults
Tota
l α-C
rypt
oxan
thin
, μg/
mL
Tota
l Lut
ein,
μg/
mL
Tota
l Zea
xant
hin,
μg/
mL
Tota
l Lut
ein&
Zeax
anth
in, μ
g/m
L La
b43
2 43
3 43
4 43
5 43
6 BS
-1a
BS-1
b
C5
FSV-
BAFS
V-BD
FSV-
BEFS
V-BH
FSV-
BJFS
V-BL
FSV-
BMFS
V-BN
FSV-
BRFS
V-BS
FSV-
BT0.
012
0.00
8 0.
015
0.01
5 0.
021
0.04
4 0.
046
FSV-
BUFS
V-BW
FSV-
CD
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Rou
nd R
obin
LX
XX
I Lab
orat
ory
Res
ults
Coe
nzym
e Q
10, μ
g/m
L Ph
yllo
quin
one
(K1)
, ng/
mL
25-h
ydro
xyvi
tam
in D
, μg/
mL
Phyt
oene
, μg/
mL
Lab
432
433
434
435
436
BS-1
a BS
-1b
C6
FSV-
BAFS
V-BD
FSV-
BEFS
V-BH
FSV-
BJFS
V-BL
FSV-
BMFS
V-BN
FSV-
BRFS
V-BS
FSV-
BTFS
V-BU
FSV-
BWFS
V-C
DFS
V-C
EFS
V-C
FFS
V-C
GFS
V-C
IFS
V-C
ZFS
V-D
VFS
V-EE
FSV-
FZFS
V-G
DFS
V-G
EFS
V-G
FFS
V-G
GFS
V-G
JFS
V-G
KFS
V-G
L
0.81
0 0.
610
1.45
0 1.
090
1.58
0
0.86
3 0.
514
1.17
8 0.
709
1.14
3
0.62
0 0.
436
1.20
4 0.
755
1.31
8
0.90
0 0.
460
1.31
0 0.
680
1.38
0
0.84
6 0.
483
1.15
9 0.
830
1.40
1
0.89
0 0.
490
1.24
0 0.
800
1.42
0 1.
208
0.56
4 1.
447
0.90
4 1.
832
0.84
6 0.
469
1.18
8 0.
759
1.39
0
0.88
2 0.
517
1.32
0 0.
824
1.56
0
0.86
0 0.
440
1.14
0 0.
750
nd0.
900
0.50
0 1.
400
1.00
0 1.
500
1.00
1 0.
483
1.30
2 0.
891
1.48
7
0.41
7
0.35
3
0.23
0
0.40
1
0.35
0
0.34
6
0.35
0
0.36
0 0.
400
0.73
3
0.42
7
0.34
8
0.20
0
0.41
5
0.37
0
0.35
7
0.35
4
0.37
0 0.
400
0.70
6
432
433
434
435
436
BS-1
a BS
-1b
0.32
9 0.
227
0.69
3 0.
694
1.67
9
0.39
6 0.
304
0.87
7 1.
006
1.91
3 0.
651
0.64
5
0.34
0 0.
230
0.78
0 0.
900
2.11
0 0.
480
0.50
0
432
433
434
435
436
BS-1
a BS
-1b
na
na
na
na
na
0.07
8 0.
077
0.01
0 0.
016
0.02
2 0.
016
0.02
5 0.
090
0.08
9
0.03
8 0.
037
0.00
9 0.
020
0.01
7 0.
017
0.02
0 na
na
0.00
7 0.
013
0.01
7 0.
012
0.02
3 0.
069
0.06
9
0.00
8 0.
014
0.01
9 0.
018
0.02
2 0.
064
0.07
2
432
433
434
435
436
BS-1
a BS
-1b
nd
nd
0.15
6 nd
0.17
3 nd
nd
0.03
5 0.
053
0.16
2 0.
079
0.26
3 0.
057
0.04
0
n12
1212
1211
1010
3
33
33
2 2
44
44
4 5
5 1
12
12
1 M
in0.
620
0.43
6 1.
140
0.68
0 1.
143
0.23
0 0.
200
0.32
9 0.
227
0.69
3 0.
694
1.67
9 0.
480
0.50
0 0.
007
0.01
3 0.
017
0.01
2 0.
020
0.03
8 0.
037
0.15
6 0.
173
Med
ian
0.87
3 0.
487
1.27
1 0.
812
1.42
0 0.
357
0.37
0 0.
340
0.23
0 0.
780
0.90
0 1.
913
0.56
6 0.
573
0.00
9 0.
015
0.01
8 0.
016
0.02
2 0.
069
0.07
2 0.
035
0.05
3 0.
159
0.07
9 0.
218
0.05
7 0.
040
Max
1.20
8 0.
610
1.45
0 1.
090
1.83
2 0.
733
0.70
6 0.
396
0.30
4 0.
877
1.00
6 2.
110
0.65
1 0.
645
0.01
0 0.
020
0.02
2 0.
018
0.02
5 0.
090
0.08
9 0.
162
0.26
3 eS
D0.
040
0.04
0 0.
130
0.10
5 0.
119
0.04
0 0.
039
0.00
1 0.
002
0.00
2 0.
002
0.00
2 0.
014
0.00
6 eC
V5
810
13
811
10
911
9
11
821
8
Npa
st
910
10
8 9
10
13
Med
ianp
ast
0.86
0.
490
1.19
0.
88
1.38
0.
008
0.01
8 SD
past
0.10
0.
043
0.14
0.
15
0.25
0.
003
0.00
9
NAV
NAU
0.87
3 0.
487
1.27
1 0.
812
1.42
0 0.
340
0.23
0 0.
780
0.90
0 1.
913
0.00
9 0.
015
0.01
8 0.
016
0.02
20.
131
0.07
3 0.
191
0.12
2 0.
213
0.36
3 0.
569
0.07
10.
011
0.03
9
All L
ab R
epor
t Pa
ge 5
/ 7
1
http:SDpast0.10
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Round Robin LXXXI Laboratory Results
Analytes Reported By One Laboratory Values in µg/mL
Term N Number of (non-NIST) quantitative values reported for this analyte
Min Minimum (non-NIST) quantitative value reported Median Median (non-NIST) quantitative value reported
Max Maximum (non-NIST) quantitative value reported eSD Adjusted median absolute deviation from the median of the non-NIST results eCV Coefficient of Variation for (non-NIST) results: 100*eSD/Median
Npast Mean of N(s) from past RR(s) Medianpast Mean of Median(s) from past RR(s)
SDpast Pooled SD from past RR(s)
NAV NIST Assigned Value: ' Median for analytes reported by ≥ 5 labs NAU NIST Assigned Uncertainty: the maximum of (0.05*NAV, SD, SDpast, eSD)
The expected long-term SD, eSD, is defined in: Duewer et al., Anal Chem 1997;69(7):1406-1413.
na Not analyzed nd Not detected (i.e., no detectable peak for analyte)
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Lab FSV-BA FSV-BD FSV-BE FSV-BH FSV-BJ FSV-BL
FSV-BM FSV-BN FSV-BR FSV-BS FSV-BT FSV-BU
FSV-BW FSV-CD FSV-CE FSV-CF FSV-CG FSV-CI
FSV-CZ FSV-DV FSV-FZ FSV-GD FSV-GE FSV-GF FSV-GJ FSV-GK
Round Robin LXXXI Laboratory Results
Comparability Summary
TR aT g/bT bC aC TLy TbX L&Z Q10 1 1 1 1 1 1 2 1 1 1 2 1 1 1 2 2 2 1 1 1
3 1 1 1 2 1 1 1 1 2 2 1 1 1 1 1 2 2 1 1 1 1 2 1 2 2 2 1 1 1 1 1 1 2 2
3 1 2 4 4 4
3 2 1 1 1 1 1 2 1 1 1 1
2 3 1 1 1
2 4 2 2 2 1 1 2 1 1 2 1 1 1 1 1 1 3 1 1 4 2 1 1 1 1
1 1 1 1 1 1
2 2
1 1 1 1 3 2
1
4 2 1 4 4
Label Lab TR aT
g/bT bC aC
TLy TbX L&Z Q10
n % 1 % 2 % 3 % 4
Definition Participant code Total Retinol α-Tocopherol γ/β-Tocopherol Total β-Carotene Total α-Carotene Total Lycopene Total β-Cryptoxanthin Total Lutein & Zeaxanthin Coenzyme Q10
number of participants providing quantitative data Percent of CS = 1 (within 1 SD of medians) Percent of CS = 2 (within 2 SD of medians) Percent of CS = 3 (within 3 SD of medians) Percent of CS = 4 (3 or more SD from medians)
“Comparability Score”
−∑=
The Comparability Score (CS) summarizes your measurement performance for a given analyte relative to the consensus medians in this study. CS is the average distance (in units of standard deviation) of your measurement performance characteristics from the consensus performance. CS is calculated when the number of quantitative values you reported, Nyou, is at least two and at least six participants reported quantitative values for the analyte.
We define CS as follows:
MINIMUM 4,INTEGER 1
you Youi Median i NAU i
FSV-GL 1 2 4 1 3 4 1 n 25 26 13 16 11 13 9 8 10
TR aT g/bT bC aC TLy TbX L&Z Q10
CS = C2 2+ AP+
N
i 1
AP = Apparent Precision =
C = Concordance = % 1 60 58 77 56 55 54 78 75 70 Nyou % 2 36 31 8 25 9 31 11 13 30
1i
you
∑ =
2N% 3 0 8 0 13 18 8 0 0 0 % 4 4 4 15 6 18 8 11 13 0
i
NAU = NIST Assigned Uncertainty
For further details, please see Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance Program: Helping participants use interlaboratory comparison exercise results to improve their long-term measurement performance. Anal Chem 1999;71(9):1870-8.
Youi
N
−Median NAU i
1−you
C8 All Lab Report Page 7 / 7
-
Appendix D. Representative Individualized Report for RR81 _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Each participant in RR81 received an “Individualized Report” reflecting their reported results. Each report included a detailed analysis for analytes that were assayed by at least five participants. The following analytes met this criterion:
• Total Retinol • α-Tocopherol • γ/β-Tocopherol • Total β-Carotene • trans-β-Carotene • Total α-Carotene • Total Lycopene • Total β-Cryptoxanthin • Total Lutein • Total Lutein & Zeaxanthin • Coenzyme Q10
The following thirteen pages are the “Individualized Report” for the analytes evaluated by participant FSV-BT.
D1
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
D2
Set
9 o
f 29
Indi
vidu
aliz
ed R
ound
Rob
in L
XX
XI R
epor
t: FS
V-B
TS
umm
ary
#432
#4
33
#434
#4
35
#436
B
S-1
a B
S-1
b A
naly
te
You
NA
V
n Yo
u N
AV
n
You
NA
V
n Yo
u N
AV
n
You
NA
V
n Yo
u N
AV
n
You
NA
V
n To
tal R
etin
ol
0.35
2 25
0.
353
0.29
2 0.
330
25
0.68
7 0.
670
25
0.72
6 0.
730
25
0.63
7 0.
659
25
0.25
9 0.
267
22
0.25
2 0.
267
22α-
Toco
pher
ol
6.70
6.
92
26
5.22
5.
21
26
11.9
3 12
.32
26
10.8
1 10
.73
26
17.4
5 19
.24
26
2.26
1.
95
23
2.31
1.
95
23
γ/β-
Toco
pher
ol
1.75
0 13
1.
676
1.21
6 1.
093
12
2.58
9 2.
539
13
2.14
4 2.
290
13
2.27
4 2.
180
13
0.26
2 0.
118
8 0.
255
0.11
8 8
Tota
l β-C
arot
ene
0.09
6 14
0.
106
0.12
6 0.
111
13
0.20
8 0.
192
14
0.28
7 0.
292
14
0.42
4 0.
447
14
0.77
2 0.
801
13
0.79
0 0.
801
13tra
ns-β
-Car
oten
e 0.
080
0.09
7 6
0.10
8 0.
103
6 0.
189
0.18
2 6
0.26
6 0.
257
6 0.
392
0.39
2 6
0.67
0 0.
704
6 0.
693
0.70
4 6
Tota
l cis
-β-C
arot
ene
0.00
8 0.
010
4 0.
018
0.01
0 4
0.01
9 0.
016
4 0.
022
0.02
0 4
0.03
2 0.
030
4 0.
102
0.09
8 4
0.09
7 0.
098
4 To
tal α
-Car
oten
e 0.
012
10
0.01
0 0.
024
0.02
7 10
0.
012
0.01
2 9
0.04
6 0.
056
10
0.01
4 0.
018
10
0.01
6 0.
031
9 0.
013
0.03
1 10
Tota
l Lyc
open
e 0.
220
13
0.13
6 0.
103
0.16
1 12
0.
361
0.69
0 13
0.
207
0.39
5 13
0.
532
1.07
7 13
0.
005
0.03
9 7
0.00
3 0.
039
8 tra
ns-L
ycop
ene
0.11
2 0.
121
4 0.
091
0.08
4 4
0.31
7 0.
306
4 0.
186
0.19
5 4
0.48
0 0.
483
4 0.
003
0.01
5 3
0.00
2 0.
015
3 To
tal β
-Cry
ptox
anth
in
0.05
7 0.
043
9 0.
025
0.03
2 7
0.04
1 0.
049
8 0.
054
0.07
0 9
0.04
4 0.
045
8 0.
054
0.05
7 8
0.05
7 0.
057
8 To
tal α
-Cry
ptox
anth
in
0.01
2 1
0.00
8 1
0.01
5 1
0.01
5 2
0.02
1 1
0.04
4 2
0.04
6 2
Tota
l Lut
ein
0.08
2 0.
082
5 0.
037
0.03
7 5
0.09
0 0.
090
5 0.
067
0.06
7 5
0.10
3 0.
103
5 0.
017
0.01
2 5
0.01
6 0.
012
5 To
tal Z
eaxa
nthi
n 0.
042
0.03
6 4
0.01
6 0.
013
4 0.
031
0.03
5 4
0.02
8 0.
033
4 0.
025
0.02
7 4
0.00
6 0.
006
4 0.
008
0.00
6 4
Tota
l Lut
ein&
Zeax
anth
in
0.11
5 0.
118
8 0.
053
0.05
4 7
0.12
1 0.
123
8 0.
095
0.09
7 8
0.12
8 0.
136
8 0.
023
0.01
9 7
0.02
4 0.
019
6 C
oenz
yme
Q10
0.
873
12
0.62
0 0.
436
0.48
7 12
1.
204
1.27
1 12
0.
755
0.81
2 12
1.
318
1.42
0 11
0.
353
0.36
3 10
0.
348
0.36
3 10
You
: Yo
ur re
porte
d va
lues
for t
he li
sted
ana
lyte
s (m
icro
gram
s/m
illili
ter)
NAV
:
NIS
T As
sign
ed V
alue
s, h
ere
equa
l to
this
RR
's m
edia
n:
Num
ber o
f non
-NIS
T la
bora
torie
s re
porti
ng q
uant
itativ
e va
lues
for t
his
anal
yte
in th
is s
erum
n
Plea
se c
heck
our
reco
rds
agai
nst y
our r
ecor
ds.
Send
cor
rect
ions
and
/or u
pdat
es to
...
Mic
ronu
trien
ts M
easu
rem
ent Q
ualit
y As
sura
nce
Prog
ram
Nat
iona
l Ins
titut
e of
Sta
ndar
ds a
nd T
echn
olog
y Te
l: (3
01) 9
75-3
935
100
Bure
au D
rive
Stop
839
2 Fa
x: (3
01) 9
77-0
685
Gai
ther
sbur
g, M
D
2089
9-83
92 U
SA
Emai
l: da
vid.
duew
er@
nist
.gov
Indi
vidu
aliz
ed R
epor
t P
age
1 / 1
3
mailto:[email protected]
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total Retinol, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D3 Page 2 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT α-Tocopherol, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D4 Page 3 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT γ/β-Tocopherol, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D5 Page 4 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total β-Carotene, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D6 Page 5 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT trans-β-Carotene, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D7 Page 6 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total α-Carotene, μg/mL
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b
Concordance, SD
Appa
rent
Pre
cisi
on, S
D
Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D8 Page 7 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total Lycopene, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D9 Page 8 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total β-Cryptoxanthin, μg/mL
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b
Concordance, SD
Appa
rent
Pre
cisi
on, S
D
Median [Analyte], µg/mL
Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D10 Page 9 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total Lutein, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D11 Page 10 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Total Lutein&Zeaxanthin, μg/mL
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b
Concordance, SD
Appa
rent
Pre
cisi
on, S
D
Median [Analyte], µg/mL
Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D12 Page 11 / 13
-
Set 9 of 29
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Individualized RR LXXXI Report: FSV-BT Coenzyme Q10, μg/mL
357
365
375
389
398
403
427
432
428
433
430
434
356
360
376
391
435
359
363
373
379
400
405
429
436
BS-1
a BS
-1b Median [Analyte], µg/mL
Appa
rent
Pre
cisi
on, S
D
[Ana
lyte]
, µg/
mL
Your
[Ana
lyte]
, µg/
mL
Appa
rent
Pre
cisi
on, S
D
Concordance, SD Long-term Precision, SD
3rd Quartile (75%) You, this RR You, ≥x, this RR
Median (50%) You, past RRs You, ≥x, past RRs Others, this RR
1st Quartile (25%) Expectation
For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.
Serum Comments History RR66#357, RR67#365, RR69#375, RR72#389, RR74#398, #432 Fresh-frozen, native, multi-donor: SRM 968e-I RR75#403, RR80#427
#433 Fresh-frozen, native, multi-donor: SRM968f-Lv1 RR80#428 #434 Fresh-frozen, native, multi-donor: SRM968f-Lv2 RR80#430 #435 Fresh-frozen, native, multi-donor 65#356, 66#360, 69#376, 71#391
RR66#359, RR67#363, RR69#373, RR70#379, RR74#400, #436 Fresh-frozen, native, multi-donor: SRM968e-III RR75#405, RR80#429 BS-1a Fresh-frozen bovine serum First distribution, Optional sample BS-1b Same material as BS-1a
Individualized Report D13 Page 12 / 13
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
Set 9
of 3
0
Indi
vidu
aliz
ed R
ound
Rob
in L
XX
XI R
epor
t: FS
V-B
TG
raph
ical
Com
para
bilit
y S
umm
ary
Tota
l Ret
inol
α-
Toco
pher
ol
Tota
l β-C
arot
ene
Tota
l Lut
ein
D14
Tota
l Lyc
open
e γ/
β-To
coph
erol
tra
ns-β
-Car
oten
e To
tal L
utei
n&Ze
axan
thin
Tota
l α-C
arot
ene
Tota
l β-C
rypt
oxan
thin
C
oenz
yme
Q10
Indi
vidu
aliz
ed R
epor
t Pa
ge 1
3 / 1
3
-
Appendix E. Final Report for RR82 _____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The following two pages are the final report for RR82 as provided to all participants: • Cover letter. • An information sheet that:
o describes the contents of the “All-Lab” report, o describes the content of the “Individualized” report, o describes the nature of the test samples and details their previous distributions,
if any, and o summarizes aspects of the study that we believe may be of interest to the
participants.
E1
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-8390
October 27, 2017
Dear Colleague:
Enclosed is the summary report of the results for “Round Robin” LXXXII (RR82) of the 2017 NIST Micronutrients Measurement Quality Assurance Program (MMQAP) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability. RR82 (Sera 437 to 441) consisted of one vial each of five liquid-frozen serum samples. Details regarding the samples can be found in the enclosed report.
Your overall measurement comparability is summarized in the “Score Card” summary, page 7 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are >3 standard deviations from the assigned value. Similar information is presented graphically in the “target plots” that are the last page of your Individualized Report. If you have concerns regarding your laboratory’s performance, please contact us for consultation.
Please note that this is the final summary report for the MMQAP. New QA studies will begin in Spring 2018 as part of the Health Assessment Measurements Quality Assurance Program (HAMQAP). We hope that you will find the HAMQAP useful. As mentioned in previous correspondence, you will be able to sign up for the new program this fall. You will be notified via email when sign-up begins. If you have questions about HAMQAP, please do not hesitate to contact us at [email protected].
If you have questions or concerns regarding this report, please contact David Duewer at 301-975-3935; e-mail: [email protected] or me at 301-975-3120; e-mail: [email protected]; or fax: 301-978-0685.
Thank you for your participation in the MMQAP. It was a pleasure working with you.
Sincerely,
Jeanice Brown Thomas, MBA David L. Duewer, Ph.D. Research Chemist Research Chemometrician Chemical Sciences Division Chemical Sciences Division Material Measurement Laboratory Material Measurement Laboratory
Enclosures
E2
mailto:[email protected]:[email protected]:[email protected]
-
_____________________________________________________________________________________________________ This publication is available free of charge from
https://doi.org/10.6028/NIS
T.IR.7880-48
The NIST MMQAP Round Robin LXXXI (RR82) report consists of: Page
1-4 A listing of all results and statistics for analytes reported by more than one participant.
5 The legend for the list of results and statistics.
6 The text Comparability Summary (Score Card) of measurement performance.
Page Individualized Report
1
2 to n
n+1
Samples. Sample
437
438
439
440
441
Results
All-Lab Report
Your values, the number of labs reporting values, and our assigned values.
“Four Plot” summaries of your current and past measurement performance, one page for each analyte you report that is also reported by at least eight other participants.
The graphical Comparability Summary (Target Plot) of measurement performance.
Five different liquid-frozen human serum samples were distributed to each participant. Description
Fresh-frozen native multi-donor plasma, prepared in 2009. This is SRM 1950.
Fresh-frozen native multi-donor serum, prepared in 2015. This is level 1 of SRM 968f.
Fresh-frozen native multi-donor serum, prepared in 2015. This is level 2 of SRM 968f.
Fresh-frozen native multi-donor serum, prepared in 2009. This is Level 2 of SRM 968e.
Fresh-frozen native multi-donor serum, prepared in 2011. This material has relatively high content of α- and β-carotene.
Prior Distributions
#340:RR63-3/08, #350:RR64-9/08
#428:RR80-9/16, #433:RR81-3/17
#430:RR80-9/16, #434:RR81-3/17
#358:RR66-9/09, #364:RR67-3/10, #374:RR69-3/11, #386:RR71-3/12, #399:RR74-9/13, #408:RR76-9/14, #416:RR77-3/15, #426:RR79-3/16
#382:RR71-3/12, #395:RR73-3/13, #421:RR78-9/15
1) Stability: There has been no significant change in the concentration nor variability of any analyte in the four SRM materials: SRM 1950, SRM 968e-II, SRM 968f-1, and SRM 968f-2.
Several participants did report lower-than-expected values for α-tocopherol and/or total β-carotene in Sample 441, suggesting that there may have been some degradation in some units of this material. To evaluate this issue, w